Novocure Ltd (NVCR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Novocure Ltd (NVCR) has a cash flow conversion efficiency ratio of -0.041x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-13.52 Million) by net assets ($330.72 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See NVCR net asset quality index to measure how much of total assets are equity-financed.
Novocure Ltd - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Novocure Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check NVCR cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Novocure Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Novocure Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shanghai Milkground Food Tech Co Ltd
SHG:600882
|
-0.004x |
|
Qingdao Baheal Medical INC.
SHE:301015
|
0.079x |
|
LANXESS AG UNSP.ADR 1/5
F:LX9B
|
0.013x |
|
Kansai Nerolac Paints Limited
NSE:KANSAINER
|
0.031x |
|
Zhejiang Jingxin Pharmaceutical Co Ltd
SHE:002020
|
0.037x |
|
Tyra Biosciences Inc
NASDAQ:TYRA
|
-0.091x |
|
Bob's Discount Furniture, Inc.
NYSE:BOBS
|
0.046x |
|
Nuvation Bio Inc
NYSE:NUVB
|
0.016x |
Annual Cash Flow Conversion Efficiency for Novocure Ltd (2013–2025)
The table below shows the annual cash flow conversion efficiency of Novocure Ltd from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see Novocure Ltd (NVCR) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $340.47 Million | $-49.03 Million | -0.144x | -96.71% |
| 2024-12-31 | $360.18 Million | $-26.37 Million | -0.073x | +63.81% |
| 2023-12-31 | $362.50 Million | $-73.34 Million | -0.202x | -389.89% |
| 2022-12-31 | $441.17 Million | $30.79 Million | 0.070x | -65.38% |
| 2021-12-31 | $410.49 Million | $82.76 Million | 0.202x | -3.11% |
| 2020-12-31 | $476.53 Million | $99.15 Million | 0.208x | +70.23% |
| 2019-12-31 | $217.79 Million | $26.62 Million | 0.122x | +835.72% |
| 2018-12-31 | $112.26 Million | $-1.86 Million | -0.017x | +94.31% |
| 2017-12-31 | $113.56 Million | $-33.13 Million | -0.292x | +61.40% |
| 2016-12-31 | $142.34 Million | $-107.59 Million | -0.756x | -89.80% |
| 2015-12-31 | $250.82 Million | $-99.88 Million | -0.398x | +47.50% |
| 2014-12-31 | $97.88 Million | $-74.24 Million | -0.759x | -147.18% |
| 2013-12-31 | $171.78 Million | $-52.72 Million | -0.307x | -- |
About Novocure Ltd
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TT… Read more